Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ishares Msci Spain ETF (EWP) vs Zoetis Inc (ZTS) Price & Performance

Ishares Msci Spain ETFTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Ishares Msci Spain ETF vs Zoetis Inc — how do they compare? Ishares Msci Spain ETF trades at $59.11, while Zoetis Inc trades at $76.41 (market cap $31.25B). The key difference: Zoetis Inc pays a 2.84% dividend while Ishares Msci Spain ETF pays none, and Ishares Msci Spain ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.

EWPZTS
Sector
Broad Market / FactorHealth
52-Week High
$60.28$156.76
52-Week Low
$43.90$71.91
Market Cap
$31.25B
Enterprise Value
$38.54B
Dividend Yield
2.84%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ishares Msci Spain ETF

No Aura AI signal available yet.

Zoetis Inc

ZTS trades at $74.08, down 1.74% on the day, with a bearish technical signal from moving averages. The company reported strong 2025 results including $9.47B revenue, $2.67B net income, and a 28.03% net margin, but missed Q1 2026 EPS estimates. Recent news highlights a securities class action lawsuit and the launch of Lenivia in Canada and the EU.

Despite near-term legal overhangs and a recent earnings miss, ZTS maintains robust profitability and a consensus price target of $101.43 implies significant upside. Key risks include litigation outcomes and competitive pressures in the companion animal segment, while solid cash flow and high ROE support long-term value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ishares Msci Spain ETF

EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.

Read more on EWP

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS